Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Dec;90(6):2166–2174. doi: 10.1172/JCI116102

Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.

O Sartor 1, C A McLellan 1, C E Myers 1, M M Borner 1
PMCID: PMC443367  PMID: 1281826

Abstract

Suramin, a synthetic polysulfonated anionic compound, is known to abrogate the activity of a variety of growth factors that serve as ligands for receptor-class protein-tyrosine kinases. Based on this information, we initially hypothesized that suramin treatment would be associated with decreased tyrosine phosphorylation. Upon testing this hypothesis in prostate cancer cell lines, we found that the most conspicuous effect of suramin was to increase the tyrosine phosphorylation of several distinct proteins. Further analyses indicate that suramin-induced increases in tyrosine phosphorylation represent a generalized, but not universal, phenomenon found in cell lines derived from a variety of human tissues. These rapid and specific suramin-induced alterations represent a novel finding for a non-polypeptide pharmaceutical agent and question the hypothesis that suramin exerts its antitumor action simply by abrogation of growth factor action.

Full text

PDF
2166

Images in this article

2168Image
on p.2168
2168Image
on p.2168
2168Image
on p.2168
2169Image
on p.2169
2169Image
on p.2169
2170Image
on p.2170
2170Image
on p.2170
2170Image
on p.2170
2170Image
on p.2170
2170Image
on p.2170
2172Image
on p.2172
2172Image
on p.2172
2172Image
on p.2172
2172Image
on p.2172
2173Image
on p.2173
2173Image
on p.2173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson S. A. Growth factors and cancer. Science. 1991 Nov 22;254(5035):1146–1153. doi: 10.1126/science.1659742. [DOI] [PubMed] [Google Scholar]
  2. Adams J. C., Furlong R. A., Watt F. M. Production of scatter factor by ndk, a strain of epithelial cells, and inhibition of scatter factor activity by suramin. J Cell Sci. 1991 Mar;98(Pt 3):385–394. doi: 10.1242/jcs.98.3.385. [DOI] [PubMed] [Google Scholar]
  3. Betsholtz C., Johnsson A., Heldin C. H., Westermark B. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6440–6444. doi: 10.1073/pnas.83.17.6440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brower M., Carney D. N., Oie H. K., Gazdar A. F., Minna J. D. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 1986 Feb;46(2):798–806. [PubMed] [Google Scholar]
  5. Cardinali M., Sartor O., Robbins K. C. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest. 1992 Apr;89(4):1242–1247. doi: 10.1172/JCI115708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carney D. N., Gazdar A. F., Bepler G., Guccion J. G., Marangos P. J., Moody T. W., Zweig M. H., Minna J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985 Jun;45(6):2913–2923. [PubMed] [Google Scholar]
  7. Coffey R. J., Jr, Leof E. B., Shipley G. D., Moses H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987 Jul;132(1):143–148. doi: 10.1002/jcp.1041320120. [DOI] [PubMed] [Google Scholar]
  8. Fleming T. P., Matsui T., Molloy C. J., Robbins K. C., Aaronson S. A. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8063–8067. doi: 10.1073/pnas.86.20.8063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289–322. doi: 10.1016/s1054-3589(08)60486-x. [DOI] [PubMed] [Google Scholar]
  10. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985;29(3):265–273. doi: 10.1002/jcb.240290310. [DOI] [PubMed] [Google Scholar]
  11. Hoyle C. H., Knight G. E., Burnstock G. Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli. Br J Pharmacol. 1990 Mar;99(3):617–621. doi: 10.1111/j.1476-5381.1990.tb12979.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang J. S., Nishimura J., Huang S. S., Deuel T. F. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity. J Cell Biochem. 1984;26(4):205–220. doi: 10.1002/jcb.240260402. [DOI] [PubMed] [Google Scholar]
  13. Kanner S. B., Reynolds A. B., Vines R. R., Parsons J. T. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A. 1990 May;87(9):3328–3332. doi: 10.1073/pnas.87.9.3328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kaplan D. R., Morrison D. K., Wong G., McCormick F., Williams L. T. PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex. Cell. 1990 Apr 6;61(1):125–133. doi: 10.1016/0092-8674(90)90220-9. [DOI] [PubMed] [Google Scholar]
  15. Kim J. H., Sherwood E. R., Sutkowski D. M., Lee C., Kozlowski J. M. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J Urol. 1991 Jul;146(1):171–176. doi: 10.1016/s0022-5347(17)37747-9. [DOI] [PubMed] [Google Scholar]
  16. Klein R., Martin-Zanca D., Barbacid M., Parada L. F. Expression of the tyrosine kinase receptor gene trkB is confined to the murine embryonic and adult nervous system. Development. 1990 Aug;109(4):845–850. doi: 10.1242/dev.109.4.845. [DOI] [PubMed] [Google Scholar]
  17. Kumjian D. A., Wahl M. I., Rhee S. G., Daniel T. O. Platelet-derived growth factor (PDGF) binding promotes physical association of PDGF receptor with phospholipase C. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8232–8236. doi: 10.1073/pnas.86.21.8232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LaRocca R. V., Cooper M. R., Uhrich M., Danesi R., Walther M. M., Linehan W. M., Myers C. E. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am. 1991 Feb;18(1):123–129. [PubMed] [Google Scholar]
  19. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  20. Martin-Zanca D., Barbacid M., Parada L. F. Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev. 1990 May;4(5):683–694. doi: 10.1101/gad.4.5.683. [DOI] [PubMed] [Google Scholar]
  21. Meisenhelder J., Suh P. G., Rhee S. G., Hunter T. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell. 1989 Jun 30;57(7):1109–1122. doi: 10.1016/0092-8674(89)90048-2. [DOI] [PubMed] [Google Scholar]
  22. Mills G. B., Zhang N., May C., Hill M., Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res. 1990 May 15;50(10):3036–3042. [PubMed] [Google Scholar]
  23. Molloy C. J., Bottaro D. P., Fleming T. P., Marshall M. S., Gibbs J. B., Aaronson S. A. PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature. 1989 Dec 7;342(6250):711–714. doi: 10.1038/342711a0. [DOI] [PubMed] [Google Scholar]
  24. Moscatelli D., Quarto N. Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol. 1989 Nov;109(5):2519–2527. doi: 10.1083/jcb.109.5.2519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Neufeld G., Gospodarowicz D. Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J Cell Physiol. 1987 Aug;132(2):287–294. doi: 10.1002/jcp.1041320213. [DOI] [PubMed] [Google Scholar]
  26. Park J. G., Oie H. K., Sugarbaker P. H., Henslee J. G., Chen T. R., Johnson B. E., Gazdar A. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res. 1987 Dec 15;47(24 Pt 1):6710–6718. [PubMed] [Google Scholar]
  27. Sartor O., Sameshima J. H., Robbins K. C. Differential association of cellular proteins with family protein-tyrosine kinases. J Biol Chem. 1991 Apr 5;266(10):6462–6466. [PubMed] [Google Scholar]
  28. Scher H. I., Jodrell D. I., Iversen J. M., Curley T., Tong W., Egorin M. J., Forrest A. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 1992 Jan 1;52(1):64–70. [PubMed] [Google Scholar]
  29. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. doi: 10.1200/JCO.1989.7.4.499. [DOI] [PubMed] [Google Scholar]
  30. Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 1988 Nov;3(5):571–578. [PubMed] [Google Scholar]
  31. Taniguchi T., Kobayashi T., Kondo J., Takahashi K., Nakamura H., Suzuki J., Nagai K., Yamada T., Nakamura S., Yamamura H. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991 Aug 25;266(24):15790–15796. [PubMed] [Google Scholar]
  32. Williams L. T., Tremble P. M., Lavin M. F., Sunday M. E. Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem. 1984 Apr 25;259(8):5287–5294. [PubMed] [Google Scholar]
  33. Yayon A., Klagsbrun M. Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5346–5350. doi: 10.1073/pnas.87.14.5346. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES